

# Giannicola Genovese

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/7847629/giannicola-genovese-publications-by-citations.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

46  
papers

8,023  
citations

27  
h-index

54  
g-index

54  
ext. papers

10,101  
ext. citations

17.1  
avg, IF

4.6  
L-index

#	Paper	IF	Citations
46	The somatic genomic landscape of glioblastoma. <i>Cell</i> , <b>2013</b> , 155, 462-77	56.2	2900
45	Genomic Classification of Cutaneous Melanoma. <i>Cell</i> , <b>2015</b> , 161, 1681-96	56.2	1807
44	Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. <i>Nature</i> , <b>2014</b> , 514, 628-32	50.4	727
43	Emerging insights into the molecular and cellular basis of glioblastoma. <i>Genes and Development</i> , <b>2012</b> , 26, 756-84	12.6	388
42	Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. <i>Nature Medicine</i> , <b>2012</b> , 18, 1503-10	50.5	270
41	Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. <i>Cell Reports</i> , <b>2017</b> , 18, 2780-2794	10.6	247
40	Passenger deletions generate therapeutic vulnerabilities in cancer. <i>Nature</i> , <b>2012</b> , 488, 337-42	50.4	224
39	Post-translational Regulation of Cas9 during G1 Enhances Homology-Directed Repair. <i>Cell Reports</i> , <b>2016</b> , 14, 1555-1566	10.6	175
38	Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. <i>Nature</i> , <b>2017</b> , 542, 119-123	50.4	145
37	The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF. <i>Cancer Research</i> , <b>2014</b> , 74, 4845-4852	10.1	111
36	microRNA regulatory network inference identifies miR-34a as a novel regulator of TGF- $\beta$ signaling in glioblastoma. <i>Cancer Discovery</i> , <b>2012</b> , 2, 736-49	24.4	90
35	InVivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer. <i>Cell Reports</i> , <b>2016</b> , 16, 133-147	10.6	77
34	Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. <i>Nature</i> , <b>2017</b> , 542, 362-366	50.4	70
33	Telomere dysfunction drives aberrant hematopoietic differentiation and myelodysplastic syndrome. <i>Cancer Cell</i> , <b>2015</b> , 27, 644-57	24.3	68
32	Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer. <i>Cancer Research</i> , <b>2015</b> , 75, 1091-101	10.1	53
31	Oncogenic KRAS-Driven Metabolic Reprogramming in Pancreatic Cancer Cells Utilizes Cytokines from the Tumor Microenvironment. <i>Cancer Discovery</i> , <b>2020</b> , 10, 608-625	24.4	52
30	Increased expression of CD133 and reduced dystroglycan expression are strong predictors of poor outcome in colon cancer patients. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2012</b> , 31, 71	12.8	42

29	Actein inhibits the Na <sup>+</sup> -K <sup>+</sup> -ATPase and enhances the growth inhibitory effect of digitoxin on human breast cancer cells. <i>Biochemical and Biophysical Research Communications</i> , <b>2008</b> , 375, 608-13	3.4	37
28	Pre-existing Functional Heterogeneity of Tumorigenic Compartment as the Origin of Chemoresistance in Pancreatic Tumors. <i>Cell Reports</i> , <b>2019</b> , 26, 1518-1532.e9	10.6	36
27	The tumor suppressor HINT1 regulates MITF and Eatenin transcriptional activity in melanoma cells. <i>Cell Cycle</i> , <b>2012</b> , 11, 2206-15	4.7	33
26	p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors. <i>Cancer Cell</i> , <b>2019</b> , 35, 204-220.e9	24.3	32
25	Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma. <i>Cancer Cell</i> , <b>2020</b> , 37, 720-734.e13	24.3	32
24	Role of Epithelial-to-Mesenchymal Transition in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , <b>2019</b> , 13, 659-668	1.5	32
23	Post-translational modulation of CD133 expression during sodium butyrate-induced differentiation of HT29 human colon cancer cells: implications for its detection. <i>Journal of Cellular Physiology</i> , <b>2010</b> , 224, 234-41	7	31
22	The Somatic Genomic Landscape of Glioblastoma. <i>Cell</i> , <b>2014</b> , 157, 753	56.2	29
21	Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma. <i>Clinical Genitourinary Cancer</i> , <b>2019</b> , 17, 1-6	3.3	28
20	Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. <i>Nature Communications</i> , <b>2021</b> , 12, 808	17.4	26
19	Expression of dystroglycan correlates with tumor grade and predicts survival in renal cell carcinoma. <i>Cancer Biology and Therapy</i> , <b>2007</b> , 6, 1840-6	4.6	25
18	Identification of Sp1 and GC-boxes as transcriptional regulators of mouse Dag1 gene promoter. <i>American Journal of Physiology - Cell Physiology</i> , <b>2009</b> , 297, C1113-23	5.4	20
17	Loss of nuclear p27(kip1) and Ekdystroglycan is a frequent event and is a strong predictor of poor outcome in renal cell carcinoma. <i>Cancer Science</i> , <b>2010</b> , 101, 2080-6	6.9	18
16	Recent advancements in the treatment of metastatic clear cell renal cell carcinoma: A review of the evidence using second-generation p-values. <i>Cancer Treatment and Research Communications</i> , <b>2020</b> , 23, 100166	2	14
15	Epithelial memory of inflammation limits tissue damage while promoting pancreatic tumorigenesis. <i>Science</i> , <b>2021</b> , 373, eabj0486	33.3	14
14	Systemic Therapies for the Management of Non-Clear Cell Renal Cell Carcinoma: What Works, What Doesn't, and What the Future Holds. <i>Clinical Genitourinary Cancer</i> , <b>2021</b> , 19, 103-116	3.3	13
13	Loss of ARID1A Promotes Epithelial-Mesenchymal Transition and Sensitizes Pancreatic Tumors to Proteotoxic Stress. <i>Cancer Research</i> , <b>2021</b> , 81, 332-343	10.1	7
12	TAM kinase inhibition and immune checkpoint blockade- a winning combination in cancer treatment?. <i>Expert Opinion on Therapeutic Targets</i> , <b>2021</b> , 25, 141-151	6.4	6

11	Leukotrienes, a potential target for Covid-19. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , <b>2020</b> , 161, 102174	2.8	5
10	Sequential Administration of XPO1 and ATR Inhibitors Enhances Therapeutic Response in TP53-mutated Colorectal Cancer. <i>Gastroenterology</i> , <b>2021</b> , 161, 196-210	13.3	5
9	PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma. <i>Nature Communications</i> , <b>2021</b> , 12, 4626	17.4	4
8	Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer. <i>European Urology Oncology</i> , <b>2021</b> ,	6.7	3
7	Association of High-Intensity Exercise with Renal Medullary Carcinoma in Individuals with Sickle Cell Trait: Clinical Observations and Experimental Animal Studies. <i>Cancers</i> , <b>2021</b> , 13,	6.6	3
6	Cancer Genetics and Therapeutic Opportunities in Urologic Practice. <i>Cancers</i> , <b>2020</b> , 12,	6.6	2
5	Molecular hallmarks of renal medullary carcinoma: more to c-MYC than meets the eye. <i>Molecular and Cellular Oncology</i> , <b>2020</b> , 7, 1777060	1.2	2
4	Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma. <i>Cancers</i> , <b>2021</b> , 13,	6.6	2
3	Medium-Chain Acyl-CoA Dehydrogenase Protects Mitochondria from Lipid Peroxidation in Glioblastoma. <i>Cancer Discovery</i> , <b>2021</b> , 11, 2904-2923	24.4	2
2	Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma. <i>Clinical Genitourinary Cancer</i> , <b>2021</b> ,	3.3	1
1	Multi-site desmoplastic small round cell tumors are genetically related and immune-cold.. <i>Npj Precision Oncology</i> , <b>2022</b> , 6, 21	9.8	1